Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | AXL | P30530 | 6/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | NEK1 | Q96PY6 | 4/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856307 | 0.88 | AAK1 (0.45) | BRD4AAK1AXLCDK2NEK1 | |
| SCHEMBL414831 | 0.87 | BRD4 (0.48) | BRD4AAK1RIPK1AXLCDK2 | |
| SCHEMBL414830 | 0.87 | BRD4 (0.48) | BRD4AAK1RIPK1AXLCDK2 | |
| SCHEMBL856016 | 0.86 | AAK1 (0.45) | BRD4AAK1AXLCDK2NEK1 | |
| SCHEMBL414740 | 0.82 | RIPK1 (0.60) | BRD4AAK1RIPK1AXLCDK2 | |
| SCHEMBL413707 | 0.79 | AAK1 (0.56) | BRD4AAK1RIPK1CDK2CCNT1 | |
| SCHEMBL417058 | 0.78 | RIPK1 (0.58) | BRD4AAK1RIPK1NTRK1FYN | |
| SCHEMBL413564 | 0.77 | TNIK (0.52) | BRD4AAK1RIPK1NTRK1IGF1R | |
| SCHEMBL411334 | 0.76 | AAK1 (0.48) | BRD4AAK1AXLCDK2NEK1 | |
| SCHEMBL411335 | 0.76 | AAK1 (0.48) | BRD4AAK1AXLCDK2NEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20130303534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8143271-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-01-26 | — | — | US | disclosed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRD4 727/4885AAK1 335/4885RIPK1 507/4885 |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRD4 727/4885AAK1 335/4885RIPK1 507/4885 |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRD4 727/4885AAK1 335/4885RIPK1 507/4885 |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRD4 727/4885AAK1 335/4885RIPK1 507/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRD4 727/4885AAK1 335/4885RIPK1 507/4885 |
| US-20130303534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRD4 727/4885AAK1 335/4885RIPK1 507/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRD4 727/4885AAK1 335/4885RIPK1 507/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRD4 727/4885AAK1 335/4885RIPK1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.